Tempus, an AI-powered precision medicine company, announced an additional $100 million financing in Series G funding round, at a post-money valuation of $5 billion.
Investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, and funds and accounts managed by T. Rowe Price.
The company plans to use the additional funds to further enhance its operations and continue its expansion into other disease areas, including diabetes, depression, and cardiology.
The latest round brings the company’s total funding to date to over $600 million.
Tempus is a precision medicine technology company building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. Its precision medicine platform enables physicians to deliver personalized cancer care for patients through our interactive analytical and machine learning platform.
The company also provides genomic sequencing services and analyze molecular and therapeutic data to empower physicians to make real-time, data-driven decisions.
“As a leader in bringing the power and promise of artificial intelligence to healthcare, we’re mindful of the size and scope of the opportunity in front us,” said Eric Lefkofsky, Founder and CEO at Tempus. “The latest fundraising will enhance our ability to forward invest in new disease areas and geographies.”
Tempus works with thousands of oncologists across hundreds of medical systems, including over two-thirds of all Academic Medical Centers, touching roughly 30% of all cancer patients in the U.S.